Nephrogen, Inc. is a seed-stage biotech company based in Bethel, ME, dedicated to developing curative gene therapies for life-threatening kidney diseases. With a focus on autosomal dominant polycystic kidney disease (ADPKD), which currently has no cure or effective treatment, Nephrogen aims to provide a groundbreaking solution that halts the disease from its onset and offers a complete cure. Their innovative technology combines CRISPR-Cas genome editing with advanced nucleic delivery methods, such as adeno-associated viruses (AAVs), to target kidney disease at its source. With a strong emphasis on precision therapy delivery and a personalized approach, Nephrogen's mission is to revolutionize therapeutics for kidney diseases and transform the lives of patients.
Generated from the website